Navigation Links
Champions Oncology Names Angela Davies, M.D., Chief Medical Officer

HACKENSACK, N.J., Jan. 6, 2014 /PRNewswire/ -- Champions Oncology (OTC: CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced the appointment of Angela Davies, M.D., as Chief Medical Officer.

Dr. Davies has demonstrated leadership and success in both academic clinical practice and as an executive in the pharmaceutical industry. Previously, she was Chief Medical Officer of OSI Pharmaceuticals where she led the clinical development program for Tarceva® (erlotinib), as well as other pipeline products, until the company's acquisition by Astellas Pharma. Earlier in her career she was an Associate Professor of Medicine at the University of California, Davis, where she practiced as a medical oncologist and was a principal investigator on NCI sponsored and investigator initiated clinical trials, specializing in thoracic malignancies and development therapeutics.

"Dr. Davies' blend of expertise will enable Champions Oncology to strengthen our relationships with pharmaceutical companies looking to improve drug discovery efforts as well as practicing oncologists seeking new treatment options for patients," said Ronnie Morris, M.D., President of Champions Oncology. "Her unique perspective is a great asset to Champions Oncology and we are pleased to have her join the team."

"As a practicing oncologist, I saw many patients with limited treatment options and highly aggressive cancers that left little time to test therapies," added Dr. Davies. "The ability to evaluate potential treatments with no risk to the patient and in a model highly correlative to the patient's own tumor would have been a great tool for my practice. I look forward to advancing this technology to enable oncologists, patients and drug developers, to benefit from this approach."  

Dr. Davies most recently served as Chief Medical Officer of Novocure, where she was responsible for the company's global clinical development and medical safety programs, and worked closely with the Global Commercialization Team in launching a newly approved medical device for the primary brain tumor, recurrent glioblastoma. During her tenure at OSI, Dr. Davies was adjunct clinical faculty at the University of Colorado Cancer Center. With her move to the east coast, Dr. Davies will continue clinical practice as adjunct clinical faculty at Smilow Cancer Hospital at Yale-New Haven. Dr. Davies has authored or co-authored more than 60 publications in peer-reviewed journals and books and more than 45 abstracts for scientific meetings. She has also held various positions of leadership in the oncology community, including a position on ASCO's Scientific Committee on thoracic malignancies as well as a position on the editorial board of Clinical Lung Cancer. Dr. Davies obtained her medical degree at McMaster University in Ontario, Canada, and her internal medicine and medical oncology training at the University of Toronto and McMaster University.

About Champions Oncology

Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The company's TumorGraft™ technology platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments, or TumorGrafts, in a manner that preserves the biological characteristics of the original human tumor in order to determine the efficacy of a treatment regimen. The company uses this technology in conjunction with related services to offer solutions for two customer groups: Personalized Oncology Solutions, in which results help guide the development of personalized treatment plans, and Translational Oncology Solutions, in which pharmaceutical and biotechnology companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs. TumorGrafts are procured through agreements with a number of institutions in the United States and overseas as well as through the company's Personalized Oncology Solutions business. For more information, please visit

SOURCE Champions Oncology
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Astellas to Host Executive Womens Day at 2013 TOUR Championship by Coca-Cola
2. Dr. Helen Fisher to Speak at Astellas Presents Executive Womens Day at the Constellation SENIOR PLAYERS Championship
3. Novation Champions Reusable Packaging for Sustainability in Healthcare
4. Champions Oncology Reports Financial Results for the Quarter Ended July 31, 2012
5. Champions Oncology to Present at Rodman & Renshaw Conference
6. Champions Oncology Reports Resignation Of Director
7. Four Californians Selected As Breakaway from Cancer® Champions To Be Honored During Amgen Tour of California
8. Sutro Biopharma Closes $26 Million Financing, Expands Development of Novel Immuno-Oncology Products
9. Ibrutinib Data Published in The Lancet Oncology Suggest a Positive Effect in Previously Untreated Chronic Lymphocytic Leukemia Patients Over Age 65
10. FLAG Therapeutics and Duquesne University Announce Exclusive Worldwide Licensing Agreement for Novel, Dual-action Targeted Oncology Compounds
11. Eisai Oncology to Present New Research on Eribulin and NEPA at 36th Annual San Antonio Breast Cancer Symposium
Post Your Comments:
(Date:11/25/2015)... WILMINGTON, N.C. , Nov. 25, 2015 /PRNewswire/ ... announces the planned investment of at least $15.8 ... in Wilmington, NC . The ... services capacity to meet the growing demands of ... Wilmington site expansion will provide up ...
(Date:11/25/2015)... , Nov. 25, 2015 Allergan plc (NYSE: ... agreement with the New York State ... of the Sherman Act, and other statutes with the Attorney ... February 2014, to cease marketing and selling the now generic ... settlement, Allergan admits no liability, has released its counterclaims against ...
(Date:11/25/2015)... USP 800 applies to all healthcare ... pharmacy technicians, nurses, physicians, physician assistants, home healthcare ... covers all entities which store, prepare, transport, or ... institutions, patient treatment clinics, physicians, practice facilities, and ... --> What is the purpose of USP ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... Somu Sivaramakrishnan announced today ... owner, Somu now offers travelers, value and care based Travel Services, including exclusive ... as well as, cabin upgrades and special amenities such as, shore excursions, discounted ...
(Date:11/26/2015)... , ... November 26, 2015 , ... ... set of retro-fused, self-animating trailer titles with ProTrailer: Vintage. This newly styled ProTrailer ... classically-influenced trailer titles work with any font, giving users limitless opportunities to stylize ...
(Date:11/25/2015)... ... 2015 , ... The holiday season is jam-packed with family ... of attendees is of the utmost importance. Whether you are cooking at home ... recipes a try this holiday season. , Turkey Croquettes ,     Ingredients: ...
(Date:11/25/2015)... ... November 26, 2015 , ... Ministers, senior ... (EU), ANDI Pan African Centres of Excellence, and public R&D institutions, civil societies ... the opening of the 5th African Network for Drugs and Diagnostics Innovation, ANDI, ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dental professionals who would like ... , are invited to attend Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE course. ... OH. , As the co-founders of Advanced Implant Mentoring (AIM), Dr. Iacobelli and ...
Breaking Medicine News(10 mins):